Google
PPCB — PROPANC BIOPHARMA, INC. COMMON STOCK (Healthcare >> Biotechnology)
PPCB FAQ
What is PPCB's ROE?
PROPANC BIOPHARMA, INC. COMMON STOCK reports a Return on Equity (ROE) of -186.82%.
What is PPCB's dividend yield?
PROPANC BIOPHARMA, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is PPCB's Deepscope Quality Score?
Deepscope rates PPCB's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PPCB?
Deepscope's AI Timing Score for PPCB is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PPCB belong to?
PROPANC BIOPHARMA, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.45
Price
-0.21
(-12.65%)
Day Change
|
|
|---|
PPCB, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 26 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.45 |
| PBV / Sector |
0.34 / 4.63
GREAT
|
| Earning Per Share | -8.06 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PPCB |
| Name | PROPANC BIOPHARMA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.28 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3.30 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 302, 6 Butler Street, Camberwell, VIC, Australia, 3124
Phone: 61 3 9882 0780
Website: https://www.propanc.com
Sector: Healthcare >> Biotechnology
Description: Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
